Heart failure is common in primary care and carries a high morbidity and mortality which is associated with the degree of failure; beta-blockers, ACE inhibitors or angiotensin II receptor blockers (ARBs), and aldosterone antagonists have all been shown to reduce mortality and morbidity, but also carry a significant risk of adverse drug reactions. This evidence concerns the gene ACE and heart failure.